William F. Kiesman

956 citations

32 papers · 718 indexed · h-index 16

Co-authors: John G. Allen Mark J. Burk Jeff Zablocki Elfatih Elzein Russell C. Petter Xianglin Shi Zhili Xin Patrick R. Conlon
Topics: Adenosine and Purinergic Signaling (7 papers)Synthesis and Biological Evaluation (6 papers)Asymmetric Synthesis and Catalysis (5 papers)
Cited by: Physiology Organic Chemistry Inorganic Chemistry
Journals: Journal of the American Chemical Society Journal of Medicinal Chemistry Journal of Pharmacology and Experimental Therapeutics
Partner nations: United States Switzerland Belgium

In The Last Decade

William F. Kiesman

32 papers receiving 682 citations

Peers

Countries citing papers authored by William F. Kiesman

Since Specialization

Citations

This map shows the geographic impact of William F. Kiesman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William F. Kiesman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William F. Kiesman more than expected).

Fields of papers citing papers by William F. Kiesman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William F. Kiesman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William F. Kiesman. The network helps show where William F. Kiesman may publish in the future.

Co-authorship network of co-authors of William F. Kiesman

This figure shows the co-authorship network connecting the top 25 collaborators of William F. Kiesman. A scholar is included among the top collaborators of William F. Kiesman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William F. Kiesman. William F. Kiesman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Chelate Effect Rationalizes Observed Rate Acceleration and Enantioselectivity in BINOL‐Catalyzed Petasis Reactions 2022 ·Chemistry - A European Journal ·Fredrik Hæffner,Thomas C. Pickel,(unknown),(unknown),William F. Kiesman,Xianglin Shi	2
2	Perspectives on the Designation of Oligonucleotide Starting Materials 2021 ·Nucleic Acid Therapeutics ·William F. Kiesman,A. McPherson,Louis J. Diorazio,(unknown),Peter D. Smith,(unknown),Alec Fettes,Tiejun Wang,Martin Mehlmann,(unknown),Gary A. Held	12
3	Process Development and Large-Scale Synthesis of BTK Inhibitor BIIB068 2020 ·Organic Process Research & Development ·Chaomin Li,(unknown),(unknown),(unknown),Michael Humora,Bin Ma,Brian T. Hopkins,John P. Guzowski,(unknown),(unknown),Yiqing Lin,Steven Ferguson,Daniel B. Patience,George A. Moniz,William F. Kiesman,Erin M. O’Brien	4
4	Solid-Phase Synthesis of Phosphorothioate Oligonucleotides Using Sulfurization Byproducts for in Situ Capping 2018 ·The Journal of Organic Chemistry ·Jimin Yang,Jessica A. Stolee,Hong Jiang,Xiao Li,William F. Kiesman,Firoz D. Antia,(unknown),(unknown),Xianglin Shi	20
5	Process Development of an N-Benzylated Chloropurine at the Kilogram Scale 2015 ·Organic Process Research & Development ·Xianglin Shi,Hexi Chang,(unknown),William F. Kiesman,(unknown)	4
6	Part 3: Designation and Justification of API Starting Materials: Proposed Framework for Alignment from an Industry Perspective 2015 ·Organic Process Research & Development ·Margaret M. Faul,(unknown),(unknown),Magnus Eriksson,Zhihong Ge,(unknown),William F. Kiesman,Ingrid Mergelsberg,John D. Orr,(unknown),Gerald A. Wächter	13
7	Part 1: A Review and Perspective of the Regulatory Guidance to Support Designation and Justification of API Starting Material 2014 ·Organic Process Research & Development ·Margaret M. Faul,William F. Kiesman,(unknown),Steven I. Pfeiffer,Carl A. Busacca,Magnus Eriksson,(unknown),John D. Orr	12
8	Part 2: Designation and Justification of API Starting Materials: Current Practices across Member Companies of the IQ Consortium 2014 ·Organic Process Research & Development ·Margaret M. Faul,Carl A. Busacca,Magnus Eriksson,(unknown),William F. Kiesman,(unknown),John D. Orr,Steven I. Pfeiffer	12
9	Case Studies in the Applicability of Drug Substance Design Spaces Developed on the Laboratory Scale to Commercial Manufacturing 2014 ·Organic Process Research & Development ·Nicholas M. Thomson,Kevin D. Seibert,Srinivas Tummala,Shailendra Bordawekar,William F. Kiesman,(unknown),Brian D. Phenix,(unknown)	5
10	A1 Adenosine Receptor Antagonists, Agonists, and Allosteric Enhancers 2009 ·Handbook of experimental pharmacology ·William F. Kiesman,Elfatih Elzein,Jeff Zablocki	77
11	Convenient One‐Pot Preparation of Dimethyl Bicyclo[2.2.2]octane‐1,4‐dicarbolylate, a Key Intermediate for a Novel Adenosine A₁ Receptor Antagonist 2007 ·Synthetic Communications ·Hexi Chang,William F. Kiesman,Russell C. Petter	5
12	Norbornyllactone-substituted xanthines as adenosine A1 receptor antagonists 2006 ·Bioorganic & Medicinal Chemistry ·William F. Kiesman,Jin Zhao,Patrick R. Conlon,Russell C. Petter,Xiaowei Jin,Glenn J. Smits,(unknown),Gail W. Sullivan,Joel Linden	16
13	Tricyclic Imidazoline Derivatives as Potent and Selective Adenosine A₁Receptor Antagonists 2006 ·Journal of Medicinal Chemistry ·Chi B. Vu,William F. Kiesman,Patrick R. Conlon,Ko‐Chung Lin,(unknown),Russell C. Petter,Glenn J. Smits,(unknown),Xiaowei Jin,Liqing Chen,Jianbo Zhang	13
14	Synthesis of alkyne derivatives of a novel triazolopyrazine as A2A adenosine receptor antagonists 2004 ·Bioorganic & Medicinal Chemistry Letters ·Gang Yao,(unknown),Sha Li,G. Kumaravel,Joy Wang,Thomas M. Engber,Eric T. Whalley,Patrick R. Conlon,Hexi Chang,William F. Kiesman,Russell C. Petter	47
15	Comparison of Three Different A1 Adenosine Receptor Antagonists on Infarct Size and Multiple Cycle Ischemic Preconditioning in Anesthetized Dogs 2004 ·Journal of Pharmacology and Experimental Therapeutics ·John A. Auchampach,Xiaowei Jin,Jeannine Moore,Tina C. Wan,Laura M. Kreckler,Zhi‐Dong Ge,Jayashree Narayanan,E. Whalley,William F. Kiesman,Barry Ticho,Glenn J. Smits,Garrett J. Gross	36
16	Catalytic asymmetric hydrogenation of β-substituted α,β,γ,δ-unsaturated amino acids 1999 ·Tetrahedron Letters ·Mark J. Burk,(unknown),William F. Kiesman,John G. Allen	32
17	A convenient cross-coupling route to α,β,γ,δ-unsaturated amino acids 1997 ·Tetrahedron Letters ·Mark J. Burk,John G. Allen,William F. Kiesman,(unknown)	22
18	Detection of Aryl Radicals in Hydrodediazoniations 1997 ·The Journal of Organic Chemistry ·(unknown),William F. Kiesman	28
19	Deuteriodediazoniation: A general method for the replacement of a diazonium group by deuterium 1995 ·Journal of Labelled Compounds and Radiopharmaceuticals ·(unknown),William F. Kiesman	6
20	Efficient Catalysis of Hydrodediazoniations in Dimethylformamide 1995 ·The Journal of Organic Chemistry ·(unknown),William F. Kiesman	43

About William F. Kiesman

William F. Kiesman is a scholar working on Physiology, Organic Chemistry and Developmental Neuroscience, having authored 32 papers that have together received 718 indexed citations. Recurring topics across this work include Adenosine and Purinergic Signaling (7 papers), Synthesis and Biological Evaluation (6 papers) and Asymmetric Synthesis and Catalysis (5 papers). The work is most often cited by research in Physiology (142 citations), Organic Chemistry (397 citations) and Inorganic Chemistry (108 citations). William F. Kiesman has collaborated with scholars based in United States, Switzerland and Belgium. Frequent co-authors include John G. Allen, Mark J. Burk, Jeff Zablocki, Elfatih Elzein, Russell C. Petter, Xianglin Shi, Zhili Xin, Patrick R. Conlon, Glenn J. Smits and Xiaowei Jin. Their work appears in journals such as Journal of the American Chemical Society, Journal of Medicinal Chemistry and Journal of Pharmacology and Experimental Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact